BACKGROUND: This study aimed to evaluate autoantibodies against the native ribosomal P complex (anti-Rib-P(C)) and recombinant ribosomal P proteins (anti-Rib-P0, anti-Rib-P1, anti-Rib-P2) for their prevalence, diagnostic relevance and clinical associations in a Chinese cohort with systemic lupus erythematosus (SLE). METHODS: Anti-Rib-P, anti-dsDNA and anti-Smith antigen (Sm) antibodies were analyzed in sera from 198 patients with SLE, 33 with rheumatoid arthritis, 61 with Sjögren's syndrome and 70 healthy individuals by means of ELISA. RESULTS: Antibody prevalences were 29.8% (anti-Rib-P(C)), 33.3% (anti-Rib-P0), 42.9% (anti-Rib-P1) and 34.3% (anti-Rib-P2), at a specificity of 99%. Among SLE patients lacking anti-dsDNA and anti-Sm, 27.8% showed positive for at least one of the investigated anti-Rib-P types. The serological hit rate provided by anti-dsDNA/anti-Sm detection (72.7%) was increased upon parallel testing for anti-Rib-P(C) (77.3%) or anti-Rib-P0/P1/P2 (80.3%). Anti-Rib-P positivity was associated with disease activity, neuropsychiatric events, lupus nephritis, skin rash, lymphocytopenia, increased erythrocyte sedimentation rates, decreased complement C3/C4 and elevated IgA/IgG levels. CONCLUSION: Based on these results, antibodies against ribosomal P proteins are important complementary parameters to anti-dsDNA and anti-Sm, and should be considered for inclusion in the classification criteria for SLE. The diagnostic value of anti-Rib-P0/P1/P2 is diagnostically superior to that of anti-Rib-P(C).
BACKGROUND: This study aimed to evaluate autoantibodies against the native ribosomal P complex (anti-Rib-P(C)) and recombinant ribosomal P proteins (anti-Rib-P0, anti-Rib-P1, anti-Rib-P2) for their prevalence, diagnostic relevance and clinical associations in a Chinese cohort with systemic lupus erythematosus (SLE). METHODS: Anti-Rib-P, anti-dsDNA and anti-Smith antigen (Sm) antibodies were analyzed in sera from 198 patients with SLE, 33 with rheumatoid arthritis, 61 with Sjögren's syndrome and 70 healthy individuals by means of ELISA. RESULTS: Antibody prevalences were 29.8% (anti-Rib-P(C)), 33.3% (anti-Rib-P0), 42.9% (anti-Rib-P1) and 34.3% (anti-Rib-P2), at a specificity of 99%. Among SLEpatients lacking anti-dsDNA and anti-Sm, 27.8% showed positive for at least one of the investigated anti-Rib-P types. The serological hit rate provided by anti-dsDNA/anti-Sm detection (72.7%) was increased upon parallel testing for anti-Rib-P(C) (77.3%) or anti-Rib-P0/P1/P2 (80.3%). Anti-Rib-P positivity was associated with disease activity, neuropsychiatric events, lupus nephritis, skin rash, lymphocytopenia, increased erythrocyte sedimentation rates, decreased complement C3/C4 and elevated IgA/IgG levels. CONCLUSION: Based on these results, antibodies against ribosomal P proteins are important complementary parameters to anti-dsDNA and anti-Sm, and should be considered for inclusion in the classification criteria for SLE. The diagnostic value of anti-Rib-P0/P1/P2 is diagnostically superior to that of anti-Rib-P(C).
Authors: R Gerli; L Caponi; A Tincani; R Scorza; M G Sabbadini; M G Danieli; V De Angelis; M Cesarotti; M Piccirilli; R Quartesan; P Moretti; C Cantoni; F Franceschini; I Cavazzana; L Origgi; M Vanoli; E Bozzolo; L Ferrario; A Padovani; O Gambini; L Vanzulli; D Croce; S Bombardieri Journal: Rheumatology (Oxford) Date: 2002-12 Impact factor: 7.580
Authors: O Shovman; G Zandman-Goddard; B Gilburd; M Blank; M Ehrenfeld; S Bardechevski; L Stojanovich; P Langevitz; Y Shoenfeld Journal: Clin Exp Rheumatol Date: 2006 Nov-Dec Impact factor: 4.473
Authors: Michael Mahler; Kai Kessenbrock; Magdalena Szmyrka; Yoshinari Takasaki; Ignacio Garcia-De La Torre; Yehuda Shoenfeld; Falk Hiepe; Chen Shun-le; Carlos A von Mühlen; Henning Locht; Peter Höpfl; Allan Wiik; Westley Reeves; Marvin J Fritzler Journal: Clin Vaccine Immunol Date: 2006-01
Authors: L S Teh; M K Lee; F Wang; M Manivasagar; P J Charles; G D Nicholson; E M Hay; D A Isenberg; N Amos; B D Williams Journal: Br J Rheumatol Date: 1993-08
Authors: I E A Hoffman; B R Lauwerys; F De Keyser; T W J Huizinga; D Isenberg; L Cebecauer; J Dehoorne; R Joos; G Hendrickx; F Houssiau; D Elewaut Journal: Ann Rheum Dis Date: 2008-10-17 Impact factor: 19.103
Authors: J G Hanly; M B Urowitz; L Su; S-C Bae; C Gordon; A Clarke; S Bernatsky; A Vasudevan; D Isenberg; A Rahman; D J Wallace; P R Fortin; D Gladman; J Romero-Diaz; J Romero-Dirz; J Sanchez-Guerrero; M A Dooley; I Bruce; K Steinsson; M Khamashta; S Manzi; R Ramsey-Goldman; G Sturfelt; O Nived; R van Vollenhoven; M Ramos-Casals; C Aranow; M Mackay; K Kalunian; G S Alarcón; B J Fessler; G Ruiz-Irastorza; M Petri; S Lim; D Kamen; C Peschken; V Farewell; K Thompson; C Theriault; J T Merrill Journal: Ann Rheum Dis Date: 2011-10 Impact factor: 19.103
Authors: J G Hanly; M B Urowitz; F Siannis; V Farewell; C Gordon; S C Bae; D Isenberg; M A Dooley; A Clarke; S Bernatsky; D Gladman; P R Fortin; S Manzi; K Steinsson; I N Bruce; E Ginzler; C Aranow; D J Wallace; R Ramsey-Goldman; R van Vollenhoven; G Sturfelt; O Nived; J Sanchez-Guerrero; G S Alarcón; M Petri; M Khamashta; A Zoma; J Font; K Kalunian; J Douglas; Q Qi; K Thompson; J T Merrill Journal: Arthritis Rheum Date: 2008-03